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Abstract
Background: Initial assessment of dyspepsia often includes noninvasive testing for Helicobacter pylori infection.
Commercially available tests vary widely in cost and accuracy. Although there is extensive literature on the cost-
effectiveness of H. pylori treatment, there is little information comparing the cost-effectiveness of various currently
used, noninvasive testing strategies.
Methods: A Markov simulation was used to calculate cost per symptom-free year and cost per correct diagnosis.
Uncertainty in outcomes was estimated using probabilistic sensitivity analysis.
Results: Under the baseline assumptions, cost per symptom-free year was $122 for empiric proton pump inhibitor
(PPI) trial, and costs for the noninvasive test strategies ranged from $123 (stool antigen) to $129 (IgG/IgA
combined serology). Confidence intervals had significant overlap.
Conclusions: Under our assumptions for how testing for H. pylori infection is employed in United States medical
practice, the available noninvasive tests all have similar cost-effectiveness between one another as well as with
empiric PPI trial.
Background
Many diagnostic scenarios require a physician to choose
from among a set of related diagnostic tests. For Helico-
bacter pylori infection in the setting of dyspepsia, diagnos-
tic options include serologic tests, a stool antigen test, a
urea breath test, and invasive methods, such as endoscopy
with biopsy. These options vary with regard to cost, con-
venience, and accuracy. The decision about which test to
order may ultimately be a significant driver of downstream
economic costs and quality-of-care outcomes. The Ameri-
can Gastroenterological Association (AGA) in 2005
recommended that to diagnose Helicobacter pylori infec-
tion in patients with dyspepsia, physicians should use
either the stool antigen test or the urea breath test. [1,2]
Serologic tests were specifically not recommended due to
inferior sensitivity and specificity. The American College
of Gastroenterology (ACG) issued a similar guideline in
2007 that discussed the tradeoffs among available tests but
left the test choice up to physician judgment. [3] The test-
ing volume for H. pylori at a national reference laboratory
(ARUP Laboratories, Salt Lake City, Utah) suggests that
serology is more widely used than would be expected
under the AGA-recommended approach. ARUP received
approximately four times as many orders for H. pylori ser-
ology between April 1, 2007, and March 31, 2008, than for
either stool or breath tests. For this reason, serology is
included in the current analysis.
A number of published articles address the cost-effec-
tiveness of H. pylori management, but most of these pri-
marily compare treatment options after a patient has
already been diagnosed with H. pylori. [4-25] Others
compare early endoscopy to empiric therapy and/or
noninvasive testing. [26-32] Still others compare the
effectiveness within a small subset of tests of diagnosing
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treatment. [27-30,33-43] At least one article has assessed
cost-effectiveness of multiple noninvasive tests before
and after diagnosis. [44] Given that “test and treat”
using noninvasive tests is a common approach to unin-
vestigated dyspepsia in the United States, the specific
noninvasive test strategy becomes a key decision point.
We therefore compared the cost-effectiveness of some
of the most common noninvasive testing strategies for
H. pylori along with empiric proton pump inhibitor
(PPI) trial in the management of uninvestigated
dyspepsia.
Methods
This study compared six diagnostic strategies [Table 1]
for initial management of patients with dyspepsia. The
first step of strategies 1 through 5 was a different nonin-
vasive test, and empiric PPI therapy was included for
completeness as a sixth strategy. In order to calculate
the impact (both cost and benefit) of the choice of diag-
nostic test we had to first create a model of the
expected care process for these patients. We intention-
ally did not use an idealized care process, but rather
modeled it to reflect typical local practice for managing
dyspepsia (Figure 1). We also believe it to be a reason-
able representation of a practice patterns for dyspepsia
across much of the US.
The primary measure of outcome was the cost (US$)
per symptom-free year. As the length of triple therapy
or PPI trial is typically 14 days and this is the event of
shortest duration in the model other than initial testing,
the Markov cycle was defined as two weeks.
Key assumptions in this model include:
1. All patients enter the model with uninvestigated
dyspepsia. There is some probability that the patient has
an H. pylori infection, peptic ulcer(s), or both.
2. In keeping with AGA and ACG guidelines, the
model considers only patients younger than 55 years of
age who lack alarm features, such as bleeding or weight
loss. Accordingly, the model does not consider the
downstream costs or the medical consequences of gas-
tric cancer, perforated ulcers, and other potentially life-
threatening conditions.
3. Any patient who tests positive for H. pylori will be
administered a course of standard triple therapy (clari-
thromycin, amoxicillin, and lansoprazole).
4. If there is no relief of symptoms after initial man-
agement, or if symptoms recur, he or she will go on to
receive an endoscopy with a biopsy. This assumption
was followed not in an attempt to reflect evidence-based
practice, but rather in an attempt to reflect a “typical”
approach to dyspepsia management.
5. Following endoscopy, if triple therapy or empiric
PPI had been initially effective in relieving symptoms of
dyspepsia, and if symptoms remained unresolved or
recurred, the patient will receive long-term PPI therapy.
As above, this assumption was followed in an attempt to
reflect typical practice patterns, rather than evidence-
based practice per se.
6. Patients remain in the model for the duration of
their life.
The scenarios above were modeled by a Markov chain
Monte Carlo (MCMC) method of statistical analysis
using the TreeAge Pro software package (TreeAge Soft-
ware, Inc., Williamstown, Massachusetts). A simplified
graphical representation of the model is given in Figure
1. Variable inputs for the model are listed in Table 2.
The outcomes measured were total cost of diagnosis
and treatment in U.S. dollars and the amount of time
spent symptom-free. The cost perspective taken was
societal.
Probabilities employed in the model were based on
published literature where available. Expert opinion was
provided by one of the coauthors (JCF). Baseline costs of
tests and treatments were based on 2009 national
midpoint Medicare reimbursement rates. Second-order
probabilistic sensitivity analysis, simulating 250 trials
involving 10,000 patients each, was undertaken to measure
the extent to which parameter uncertainty might affect the
model outcomes. Incremental cost-effectiveness ratios
(ICERs) were calculated based on a single simulated
cohort of 500,000 patients using empiric PPI trial (i.e., no
testing) as the baseline for comparison.
Results
The cost-effectiveness ratios for the six initial manage-
ment strategies were similar (Table 3); stool antigen and
empiric PPI trial were essentially equivalent, and both
strategies were mildly superior to the remaining diag-
nostic test strategies. Some previously published cost-
effectiveness analyses have reported results in the form
of mean cost per correct diagnosis; to allow easier
Table 1 Description of strategies modeled
Strategy Description
IgG/IgA Begin with H. pylori IgG and IgA tests. If either is
positive, do triple therapy. If both are negative,
do PPI trial.
IgG Begin with H. pylori IgG test. If positive, do triple
therapy. If negative, do PPI trial.
Stool Antigen Begin with H. pylori stool antigen test. If positive,
do triple therapy. If negative, do PPI trial.
IgG with reflex to
stool Antigen
Begin with IgG test. If positive, confirm with
stool antigen detection. If both tests are positive,
do triple therapy. Otherwise, do PPI trial.
Breath Test Begin with H. pylori urea breath test. If positive,
do triple therapy. If negative, do PPI trial.
PPI trial Skip noninvasive testing and begin instead with
PPI trial.
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Page 2 of 6Figure 1 Diagram of H. pylori Markov model. SR = Symptoms resolve. SNR = Symptoms do not resolve. RPE = Relapse, PPI initially effective.
RPNE = Relapse, PPI not initially effective. D = Death from all causes. SCPE = Symptoms continue, PPI initially effective. SCPN = Symptoms
continue, PPI not initially effective.
Table 2 Variables employed in the model
Variable Mean Distribution 95th percentile * Reference(s)
H. pylori prevalence 0.23 Uniform 0.05 - 0.4 [3,44,46]
Initial ulcer status 0.10 Beta 0.025-.022 [1,2]
Cost of IgA serology $29 Gamma 12.53-51.34 **
Cost of IgG serology $29 Gamma 12.53-51.34 **
Cost of stool Ag detection $21 Gamma 6.20-44.56 **
Cost of urease breath test $133 Gamma 28.81-316.05 **
Cost of endoscopy w/biopsy and pathologist time $511 Gamma 156.21-2552.46 ***
Cost of eradication therapy $355 Gamma 186.55-576.02 ***
Cost of 2-week PPI therapy $40 Gamma 10.92-87.51 ***
Breath test sensitivity 0.95 Triangular 0.90 - 0.98 [28,34,39,41,44]
Breath test specificity 0.96 Triangular 0.94 - 0.99 [28,34,39,41,44]
IgA serology sensitivity 0.85 Triangular 0.79 - 0.90 [27,29-31,38,41,44,47-51]
IgA serology specificity 0.79 Triangular 0.65 - 0.85 [27,29-31,38,41,44,47-51]
IgG serology sensitivity 0.85 Triangular 0.79 - 0.90 [27,29-31,38,41,44,47-51]
IgG serology specificity 0.79 Triangular 0.65 - 0.85 [27,29-31,38,41,44,47-51]
Stool Ag sensitivity 0.93 Triangular 0.90 - 0.99 [27,30,33-35,37,40-44,52-56]
Stool Ag specificity 0.92 Triangular 0.90 - 0.99 [27,30,33-35,37,40-44,52-56]
Probability of relief of symptoms after two weeks of triple therapy (NUD§) 0.53 Beta 0.28-0.66 [57]
Probability of relief of symptoms after two weeks of triple therapy (PUD§§) 0.49 Beta 0.28-0.70 [11]
Probability of relief of symptoms after two-week PPI trial (NUD) 0.40 Beta 0.40-0.78 Expert opinion§§§
Probability of relief of symptoms after two-week PPI trial (PUD) 0.32 Beta 0.47-0.85 [11]
Probability of relapse at one year after eradication therapy (NUD) 0.32 N/A N/A [57]
Probability of relapse at one year after eradication therapy (PUD) 0.37 N/A N/A [11]
*Calculated by taking 100,000 samples from each distribution.
**These estimates are based on 2009 Medicare reimbursement rates, where the mean is the 2009 midpoint national reimbursement rate as published in the
2009 Clinical Diagnostic Laboratory Fee Schedule, which is available at http://www.cms.hhs.gov/ClinicalLabFeeSched/.
***These figures are based on Medicare reimbursement rates, which are current for 2009 CPT codes and are available from the American Medical Association.
§Non-ulcer dyspepsia.
§§Peptic ulcer disease.
§§§John C. Fang, MD, Associate Professor of Gastroenterology, University of Utah, Salt Lake City, Utah
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to this measure in Table 4. None of these results were
sensitive to changes in prevalence of H. pylori (5% to
40%).
Discussion
Assuming that this model and its assumptions reason-
ably reflect U.S. clinical practice, it appears that the
initial choice of noninvasive testing strategy does not
have a significant influence on the overall cost-effective-
ness of care for patients presenting with previously
uninvestigated dyspepsia. This finding holds even when
t h ep r e v a l e n c eo fH. pylori infection is varied over a
wide range (5% to 40%).
These findings may seem surprising; it seems intuitive
that more accurate testing should lead to improved out-
comes and lower overall health spending, provided that
the cost of the test itself is reasonable. The key, though,
is the set of baseline assumptions about how the tests
are used in U.S. clinical practice. In particular, we
assumed that in the absence of symptomatic relief, phy-
sicians would move fairly quickly to definitive diagnosis
(endoscopy with biopsy), thus reducing or even negating
the impact of the original noninvasive test (or lack
thereof). To use a more extreme illustration, a conse-
quence of our underlying model is that the diagnostic
test could be replaced with a random number generator
without significantly impacting cost-effectiveness. In set-
tings where endoscopy is less widely employed, the deci-
sion about which noninvasive test to order for a patient
would likely have a larger economic and clinical impact,
depending on the test chosen.
Vakil et al. estimated the cost-effectiveness of a similar
set of noninvasive testing strategies in a 2000 paper [44].
In their model, cost per correct diagnosis using the anti-
body and stool tests ranged from $90 to $127. The anti-
body tests incurred the lowest cost per correct diagnosis
at all levels of prevalence that they modeled (30%, 60%,
and 90%). The stool test was more expensive at low and
intermediate prevalence, but with much higher diagnos-
tic accuracy (~93%). A key distinction of our model is
that we used cost per symptom-free year rather than
cost per correct diagnosis as our primary measure,
although we did include the latter in our results for
comparison. This distinction is significant. First, the
clinical goal is typically relief of symptoms rather than
diagnosis per se. A patient is unlikely to undergo follow-
up when symptoms have been alleviated, as in the
empiric PPI trial or a PPI trial after eradication treat-
ment. The impact of the diagnosis can only be truly
assessed in the context of the resulting clinical actions.
Therefore, the cost at diagnosis does not reflect the
total cost of care. For example, a patient can have an
incorrect noninvasive test result, but if the patient still
achieves long-term relief of symptoms without incurring
too much expense, then from that patient’s
perspective, no great harm has been done. We thus
believe that cost per symptom-free year is a more
appropriate cost-effectiveness measure than cost per
correct diagnosis. In a larger sense, our study illustrates
some of the challenges in assessing cost-effectiveness of
diagnostic tests, as well as the importance of doing so.
Because testing is an upstream process, the clinical and
economic impacts of diagnostic tests are expressed pri-
marily in the downstream clinical actions. The result
from a $10 test, for example, might in some cases make
the difference between whether to provide a $10,000
course of chemotherapy or a surgical procedure. Or, in
a different scenario, that same $10 test might simply be
a waste of $10, if the same clinical actions took place
regardless of the test result. Superior sensitivity and/or
specificity does not guarantee better patient outcomes
once the test is placed in the larger context of patient
management. In other words, cost-effectiveness is less
an inherent property of a particular test than it is a
property of the decision-making algorithm in which that
test is employed. [45]
Limitations
The primary limitation of our analysis was our set of clin-
ical assumptions. These results should not be considered
to have validity outside of those assumptions. This
includes both the assumed practice pattern (Figure 1)
and the numbers (costs and probabilities). In clinical
Table 3 Cost-Effectiveness ratios for each strategy
modeled
Strategy Cost per symptom free
year (95% CI*)
Empiric PPI Trial 122.13 (120.00-124.88)
Stool Ag 123.23 (120.68-125.58)
IgG serology 125.76 (123.18-128.27)
IgG serology w/reflex to Stool Ag 126.17 (123.43-128.08)
Breath test 128.31 (125.69-130.72)
IgG/IgA binary serology 129.04 (126.43-131.48)
Numerical values are in $US per symptom-free year.
Table 4 Cost per correct diagnosis for each strategy
modeled
Testing Strategy Average Cost per Correct
Diagnosis
Stool Ag $2767.85
Breath test $2825.24
IgG Serology $3371.91
IgG serology w/reflex to Stool
Ag
$3373.39
IgG/IgA binary serology $4061.91
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not apply. Another limitation is that we did not present
our results in terms of quality-adjusted life years
(QALYs), partly because we did not find any widely used
figures for quality-of-life measurements for patients with
dyspepsia, and partly because the existing literature on
cost-effectiveness of H. pylori diagnostic tests does not
appear to rely heavily on QALY analysis. Also, as stated
above, our model was based entirely on dyspepsia relief
and did not consider more serious illnesses such as a per-
forated ulcer, gastric cancer, etc.
Finally, our analysis relied heavily on the findings of a
Cochrane systematic review [18] in which H. pylori era-
dication was found to have only a very small clinical
benefit for the average patient with nonulcer dyspepsia.
Our findings may thus not apply to patient subsets for
which eradication therapy could be shown to have a lar-
ger average benefit.
Conclusions
In this model of H. pylori diagnosis and treatment, the
choice of initial noninvasive test did not have a signifi-
cant impact on cost or quality outcome. This is likely
attributable to the assumption of a high resource inten-
sity practice environment. In practice settings where
endoscopy is less available and/or less readily employed,
these findings may not apply.
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